Tong, Hoi YanBorobia, AlbertoQuintana Díaz, ManuelFabra, SaraGonzález Viñolis, ManuelFernández Capitán, CarmenRodriguez Dávila, MaríaLorenzo, AliciaLópez Parra, Ana MaríaRuiz Giménez, NuriaAbad Santos, FranciscoSuarez, CarmenMadridano, OlgaGómez Cerezo, JorgeLlamas, PilarBaeza Richer, Carlos IgnacioArroyo Pardo, EduardoCarcas, Antonio J.2023-06-172023-06-172021-06-302077-038310.3390/jcm10132949https://hdl.handle.net/20.500.14352/7415This work was supported by a grant (TRA-010) from the Ministry of Health, Social Services and Equality of the Spanish Government and by the technical and financial support of IdiPAZ (Research Institute of La Paz University Hospital).Patients with venous thromboembolism (VTE) require immediate treatment with anticoagulants such as acenocoumarol. This multicentre randomised clinical trial evaluated the effectiveness of a dosing pharmacogenetic algorithm versus a standard-of-care dose adjustment at the beginning of acenocoumarol treatment. We included 144 patients with VTE. On the day of recruitment, a blood sample was obtained for genotyping (CYP2C9*2, CYP2C9*3, VKORC1, CYP4F2, APOE). Dose adjustment was performed on day 3 or 4 after the start of treatment according to the assigned group and the follow-up was at 12 weeks. The principal variable was the percentage of patients with an international normalised ratio (INR) within the therapeutic range on day 7. Thirty-four (47.2%) patients had an INR within the therapeutic range at day 7 after the start of treatment in the genotype-guided group compared with 14 (21.9%) in the control group (p = 0.0023). There were no significant differences in the time to achieve a stable INR, the number of INRs within the range in the first 6 weeks and at the end of study. Our results suggest the use of a pharmacogenetic algorithm for patients with VTE could be useful in achieving target INR control in the first days of treatment.Hoi Yan TongengAtribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/journal articlehttps://doi.org/10.3390/jcm10132949https://www.mdpi.com/2077-0383/10/13/2949open access611.1PharmacogeneticsAcenocoumarolVenous thromboembolismClinical trialMedicinaSistema cardiovascular32 Ciencias Médicas2411.03 Fisiología Cardiovascular